Mutations in BCR signaling components including CARD11, CD79A/B, TNFAIP3, and MYD88, have been associated with constitutive activation of BCR signaling in ABC-DLBCL via activating NF-κB pathway and resistance to ibrutinib [140,141,142]. This evidence concerns the gene CD79A and diffuse large B-cell lymphoma.